-

$undefined

N/A

(N/A)

Nkarta Therapeutics NASDAQ:NKTX Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body.

Location: | Website: www.nkartatx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-25.42M

Cash

283.1M

Avg Qtr Burn

-24.57M

Short % of Float

24.52%

Insider Ownership

5.26%

Institutional Own.

99.87%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NKX019 (CAR NK cell therapy) Details Autoimmune disease, Scleroderma, Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 (CAR NK cell therapy) Details Systemic lupus erythematosus, Autoimmune disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 (CAR NK cell therapy) Details B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 (CAR NK cell therapy) Details Lupus nephritis, Autoimmune disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX101 (CAR-T targeting NKG2D) Details Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 Details Myasthenia gravis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.